TVM Capital Life Science

General contacts
Investor type

PE / VC

Founded

1984

AUM

$900 M

Location

Munich, Bavaria, Germany

Investment Ticket

$1-5 m

Investment Stage

Seed Pre-seed Series A Series B Late Stage (Series C+)

Region of investment

North America Europe Africa Asia
Investor profile last updated: 21 August, 2026

Profile

TVM Capital Life Science is a venture capital firm based in Munich, Germany, founded in 1983. The firm specializes in life sciences investments, focusing on early-stage therapeutics and commercial-stage medtech, diagnostics, and digital health products. TVM Capital Life Science has a strategic relationship with Eli Lilly and Company, which enhances its ability to support innovative healthcare companies. The team comprises experienced professionals with over 100 years of combined venture capital and industry expertise.

The firm invests primarily in the life sciences sector, including biotechnology, pharmaceuticals, and medical devices. TVM Capital Life Science typically invests in Series A and B rounds, with a minimum investment size of $1 million. The firm operates globally, with a focus on Europe and North America, and manages assets worth approximately 900 million euros. Notable funds include TVM Life Science Innovation II, a $478 million fund launched in 2018.

TVM Capital Life Science's portfolio includes companies such as Access Vascular - surgical devices, Kent Imaging - diagnostic equipment, and LAmAb Biologics - drug discovery. The firm has a track record of successful exits, including IPOs and acquisitions, highlighting its role as a key player in the life sciences venture capital landscape.

Industry

Digital AdTech Biotechnology Healthcare Services Marketing and Advertising Medical Devices Pharmaceuticals MedTech Life Sciences HealthTech Media and Entertainment Real Estate SaaS Software Telecommunications Energy Infrastructure AI Robotics

TVM Capital Life Science Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region 		Size AUM Launch date
TVM Capital Life Science Fund II
Fund of funds
Healthcare Services
Media and Entertainment
Real Estate
SaaS
Software
Telecommunications
Energy
HealthTech
Seed
Series A
Series B
North America
Europe
$5-10 m
$478 M
October 2020
TVM Life Science Innovation II
Private Equity (PE)
Venture Capital (VC)
HealthTech
Infrastructure
Life Sciences
MedTech
AI
Robotics
Real Estate
Pharmaceuticals
Medical Devices
Marketing and Advertising
Healthcare Services
Biotechnology
AdTech
Seed
Pre-seed
Series A
Series B
Late Stage (Series C+)
North America
Europe
Africa
Asia
$10-50 m
$478 M
January 2018

Contacts

Name
Title
Email
Social Networks
avatar
Dr. Hubert Birner Managing Partner,Munich
Managing Partner,Munich
b•••@•••
avatar
Stefan Fischer Managing Partner (Finance),Munich
Managing Partner (Finance),Munich
f•••@•••
Upgrade to see contacts
avatar
TWjSKu3029Ayzwbx TWjSKu3029Ayzwbx
TWjSKu3029Ayzwbx
[email protected]
linkedin twitter
avatar
TWjSKu3029Ayzwbx TWjSKu3029Ayzwbx
TWjSKu3029Ayzwbx
[email protected]
linkedin twitter
avatar
TWjSKu3029Ayzwbx TWjSKu3029Ayzwbx
TWjSKu3029Ayzwbx
[email protected]
linkedin twitter
Investment-team contacts for TVM Capital Life Science — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about TVM Capital Life Science

TVM Capital Life Science is a venture capital and private equity firm. It backs companies at Seed, Pre-seed, Series A, Series B and Late Stage (Series C+), writing tickets of $1-5 m.
TVM Capital Life Science is located in Munich, Bavaria, Germany.
TVM Capital Life Science was founded in 1984.
TVM Capital Life Science invests in companies and startups in Digital, AdTech, Biotechnology, Healthcare Services, Marketing and Advertising, Medical Devices, Pharmaceuticals, MedTech, Life Sciences, HealthTech, Media and Entertainment, Real Estate, SaaS, Software, Telecommunications, Energy, Infrastructure, AI, Robotics.
TVM Capital Life Science invests in companies and startups in North America, Europe, Africa, Asia.
TVM Capital Life Science invests in companies and startups at Seed, Pre-seed, Series A, Series B, Late Stage (Series C+).
TVM Capital Life Science usually invests $1-5 m on average.
TVM Capital Life Science has around $900m assets under management.
TVM Capital Life Science last fund was created/launched in 2020-10-28
TVM Capital Life Science can be reached through its website tvm-capital.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for TVM Capital Life Science — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query TVM Capital Life Science directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 21 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.